The primary goal of this study, following our previous report ([@B1]), was to determine long-term safety of encapsulated human islet (HI) transplant (TX), upon completion of two additional cases. The following parameters were examined: *1*) TX-related adverse reactions; *2*) TX-directed immune destruction in nonimmunosuppressed recipients; and *3*) sensitization to grafted encapsulated islet cell antigens. We also examined *1*) changes in exogenous insulin consumption; *2*) levels of prior negative serum C-peptide response; *3*) changes in severe nocturnal hypoglycemia, defined by blood glucose (BG) \<40 mg/dL (patients 1 and 2) ([@B2]); and *4*) changes in HbA~1c~ plasma levels.

RESEARCH DESIGN AND METHODS {#s5}
===========================

Human islet procurement {#s6}
-----------------------

HIs were isolated from single donor pancreases, according to the Edmonton protocol ([@B3]). Islet preparations from our laboratory were grafted in patients 1 and 2. We also used HIs procured at the University of Illinois at Chicago (UIC) (patients 3 and 4). The "UIC HIs" were isolated using a modified Ricordi's method and passed the product release criteria including viability, purity, and endotoxin levels \<5 endotoxin units/g (EU/g), as required by the U.S. Food and Drug Administration. The UIC HIs could be used in our Center because there was no suitable U.S. recipient available for such a given islet preparation. This scenario happened because the HI yield was insufficient to achieve the required 5,000 islet equivalents (IEQ)/kg body wt of listed U.S. recipients. Islet morphology, viability, and functionality assessments were performed before and after microencapsulation, showing *1*) purity \>80%; *2*) viability \>90%; and *3*) stimulation index upon static incubation with glucose \>5 above baseline.

Islet microencapsulation {#s7}
------------------------

The selected islet batches were encapsulated in ultra-purified, endotoxin-free sodium alginate prepared in-house (patent number WO 2009/093184 A1) by our method ([@B4]).

Patient selection {#s8}
-----------------

Four patients with long-standing type 1 diabetes (T1DM) were selected, as previously reported ([@B1]).

Clinical, metabolic, and immunological evaluation {#s9}
-------------------------------------------------

All clinical and metabolic parameters were carefully acquired before and strictly monitored after TX.

### Basal pre-TX clinical assessment. {#s10}

Complete blood chemistry, including all metabolic parameters (HbA~1c~; daily glucose profiles after and 3 consecutive months before entering the trial), was performed.

### Post-TX assessment. {#s11}

All grafted patients underwent hourly BG and exogenous insulin supplement monitoring to keep BG within the prefixed range (120--150 mg/dL).

### Metabolic and immunological characterization. {#s12}

All patients, upon TX, underwent either an oral glucose tolerance test (75 g; patient 1 only) or a glucagon (1 mg i.v.) or arginine test (10 g in 250 mL saline i.v.; patient 1 only) to determine basal and poststimulation serum C-peptide response by radioimmunoassay (Myria, Milan, Italy). Islet cell antibodies, anti-GAD65 antibodies, and anti-major histocompatibility complex (MHC) class I--II antibodies were assessed before and after transplantation ([Table 1](#T1){ref-type="table"}) on a long-term follow-up basis. Anti-MHC class I--II antibodies were assessed by ELISA (Biotest, Waukesha, WI).

###### 

Summary of clinical, metabolic, and immunological data of the transplanted patients throughout long-term follow-up (patients 1 and 4 received more than one graft)

                                               Patient 2                         Patient 3                         Patient 1                                                         Patient 4
  -------------------------------------------- --------------------------------- --------------------------------- ----------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  Duration of T1DM (years)                     20                                21                                25                                                                27
  Pre-TX severe hypoglycemia (events/week)     1                                 3                                 4                                                                 4
  Post-TX severe hypoglycemia (events/week)    0                                 0                                 0                                                                 0
  Body weight at the time of transplant (kg)   78                                68                                70                                                                68
                                                                                                                   72[\*](#t1n1){ref-type="table-fn"}                                66[†](#t1n2){ref-type="table-fn"}[‡](#t1n3){ref-type="table-fn"}
  Mass of islets implanted (IEQ)               650,000                           540,000                           400,000                                                           500,000
                                                                                                                   400,000[\*](#t1n1){ref-type="table-fn"}                           500,000[†](#t1n2){ref-type="table-fn"}
                                                                                                                                                                                     600,000[‡](#t1n3){ref-type="table-fn"}
  Total islet mass (IEQ)                       NA                                NA                                800,000                                                           1,600,000
  Pre-TX mean BG (mg/dL)                       235 ± 78                          180 ± 63                          275 ± 98                                                          247 ± 55
  Post-TX mean BG (mg/dL)                                                                                                                                                            
   6 months                                    155 ± 44                          103 ± 34                          115 ± 56[\*](#t1n1){ref-type="table-fn"}                          145 ± 36[†](#t1n2){ref-type="table-fn"}[‡](#t1n3){ref-type="table-fn"}
   12 months                                   174 ± 54                          176 ± 50                          167 ± 58                                                          151 ± 18
   15 months                                   190 ± 18                          170 ± 63                          175 ± 24                                                          176 ± 12
   18 months                                   165 ± 44                          123 ± 14                          180 ± 36                                                          170 ± 38
   24 months                                   176 ± 31                          162 ± 15                          198 ± 16                                                          176 ± 26
   30 months                                   195 ± 06                          Dropout                           241 ± 20                                                          177 ± 24
   36 months                                   201 ± 41                                                            208 ± 16                                                          204 ± 16
  Pre-TX sCPR (ng/mL)                          Undetectable                      Undetectable                      Undetectable                                                      Undetectable
  Post-TX sCPR (ng/mL)                                                                                                                                                               
   3 months                                    Premeal = 0.25, postmeal = 1.00   Premeal = 0.63, postmeal = 1.30   Premeal = 0.20, postmeal = 0.90                                   Premeal = 0.57, postmeal = 1.10[†](#t1n2){ref-type="table-fn"}
   6 months                                    Premeal = 0.41, postmeal = 0.85   Premeal = 0.58, postmeal = 0.91   Premeal = 0.10, postmeal = 0.42[\*](#t1n1){ref-type="table-fn"}   Premeal = 0.33, postmeal = 0.81[†](#t1n2){ref-type="table-fn"}[‡](#t1n3){ref-type="table-fn"}
   12 months                                   Premeal = 0.35, postmeal = 0.80   Premeal = 0.40, postmeal = 0.75   Premeal = 0.25, postmeal = 0.50                                   Premeal = 0.35, postmeal = 0.73
   18 months                                   Premeal = 0.30, postmeal = 0.75   Premeal = 0.20, postmeal = 0.50   Premeal = 0.18, postmeal = 0.48                                   Premeal = 0.31, postmeal = 0.74
   24 months                                   Premeal = 0.18, postmeal = 0.61   Premeal = 0.10, postmeal = 0.44   Premeal = 0.26, postmeal = 0.58                                   Premeal = 0.35, postmeal = 0.70
   30 months                                   Premeal = 0.15, postmeal = 0.47   Dropout                           Premeal = 0.15, postmeal = 0.45                                   Premeal = 0.46, postmeal = 0.74
   36 months                                   Premeal = 0.10, postmeal = 0.51                                     Premeal = 0.26, postmeal = 0.55                                   Premeal = 0.34, postmeal = 0.76
  Daily exogenous insulin (IU) pre-TX          37                                36                                32                                                                32
  Daily exogenous insulin (IU) post-TX                                                                                                                                               
   3 months                                    29                                22                                13                                                                21[†](#t1n2){ref-type="table-fn"}
   6 months                                    22                                20                                15[\*](#t1n1){ref-type="table-fn"}                                22[†](#t1n2){ref-type="table-fn"}[‡](#t1n3){ref-type="table-fn"}
   12 months                                   22                                18                                15                                                                20
   15 months                                   28                                20                                22                                                                20
   18 months                                   28                                16                                22                                                                20
   24 months                                   30                                18                                25                                                                26
   27 months                                   30                                Dropout                           22                                                                24
   30 months                                   28                                                                  25                                                                28
   36 months                                   28                                                                  25                                                                28
  Pre-TX GHb (%)                               8.7 ± 0.3                         8.0 ± 0.6                         9.0 ± 0.2                                                         9.0 ± 0.4
  Post-TX GHb (%)                                                                                                                                                                    
   3 months                                    7.2 ± 0.4                         7.2 ± 0.4                         7.8 ± 0.4                                                         8.1 ± 0.2[†](#t1n2){ref-type="table-fn"}
   6 months                                    7.5 ± 0.3                         7.4 ± 0.2                         8.2 ± 0.3[\*](#t1n1){ref-type="table-fn"}                         7.2 ± 0.4[†](#t1n2){ref-type="table-fn"}[‡](#t1n3){ref-type="table-fn"}
   12 months                                   7.8 ± 0.3                         7.3 ± 0.3                         7.2 ± 0.1                                                         6.5 ± 0.3
   15 months                                   7.6 ± 0.2                         7.1 ± 0.5                         7.6 ± 0.4                                                         5.9 ± 0.2
   18 months                                   8.0 ± 0.1                         7.2 ± 0.1                         7.4 ± 0.2                                                         6.2 ± 0.4
   24 months                                   7.8 ± 0.3                         7.5 ± 0.3                         7.7 ± 0.4                                                         7.4 ± 0.1
   27 months                                   7.5 ± 0.4                         Dropout                           7.2 ± 0.2                                                         7.2 ± 0.2
   30 months                                   7.3 ± 0.4                                                           7.7 ± 0.3                                                         6.1 ± 0.3
   36 months                                                                                                                                                                         7.5 ± 0.1
  Metabolic function                                                                                                                                                                 
   sCPR (ng/mL), 3 months                      NA                                                                  Oral glucose tolerance test BG (mg/dL)-sCPR                       
    0 min                                                                                                          150--0.075                                                        
    30 min                                                                                                         230--0.100                                                        
    60 min                                                                                                         240--0.198                                                        
    90 min                                                                                                         280--0.130                                                        
    120 min                                                                                                        300--0.209                                                        
    180 min                                                                                                        288--0.171                                                        
    240 min                                                                                                        285--0.090                                                        
   sCPR (ng/mL), 3 months                      NA                                                                  Arginine                                                          
    0 min                                                                                                          0.26                                                              
    2 min                                                                                                          0.32                                                              
    4 min                                                                                                          0.30                                                              
    6 min                                                                                                          0.45                                                              
    8 min                                                                                                          0.31                                                              
    10 min                                                                                                         0.38                                                              
   sCPR (ng/mL), 3 months                      NA                                Glucagon test                                                                                       Glucagon test[†](#t1n2){ref-type="table-fn"}
    0 min                                                                        0.047                                                                                               0.71
    5 min                                                                        0.017                                                                                               
    10 min                                                                       1.090                                                                                               0.83
    15 min                                                                       1.480                                                                                               
    30 min                                                                       0.500                                                                                               0.95
    40 min                                                                       0.840                                                                                               0.82
    60 min                                                                       0.380                                                                                               0.99
    120 min                                                                      0.470                                                                                               0.77
   sCPR (ng/mL), 12 months                                                                                                                                                           Glucagon test[†](#t1n2){ref-type="table-fn"}[‡](#t1n3){ref-type="table-fn"}
    0 min                                                                                                                                                                            0.18
    5 min                                                                                                                                                                            0.59
    10 min                                                                                                                                                                           0.56
    15 min                                                                                                                                                                           0.62
    20 min                                                                                                                                                                           0.74
    30 min                                                                                                                                                                           0.71
    40 min                                                                                                                                                                           0.85
    50 min                                                                                                                                                                           0.90
    60 min                                                                                                                                                                           
    120 min                                                                                                                                                                          0.42
   sCPR (ng/mL), 36 months                     Dropout                           Dropout                                                                                             Glucagon test
    0 min                                                                                                                                                                            0.30
    5 min                                                                                                                                                                            0.42
    10 min                                                                                                                                                                           0.48
    15 min                                                                                                                                                                           0.89
    20 min                                                                                                                                                                           0.76
    30 min                                                                                                                                                                           0.74
    40 min                                                                                                                                                                           0.44
    50 min                                                                                                                                                                           0.37
    60 min                                                                                                                                                                           
    120 min                                                                                                                                                                          0.32
  Immune monitoring (pre-TX)                                                                                                                                                         
   Anti-GAD 65 antibodies                      Negative                          Negative                          Negative                                                          Negative
   Islet cell antibodies                       Negative                          Negative                          Negative                                                          Negative
   Class I HLA                                 Negative                          Negative                          Negative                                                          Negative
   Class II HLA                                Negative                          Negative                          Negative                                                          Negative
  Immune monitoring (3--5 years post-TX)                                                                                                                                             
   Anti-GAD 65 antibodies                      Negative                          Negative                          Negative                                                          Negative
   Islet cell antibodies                       Negative                          Negative                          Negative                                                          Negative
   Class I HLA                                 Negative                          Negative                          Negative                                                          Negative
   Class II HLA                                Negative                          Negative                          Negative                                                          Negative

sCPR, serum C-peptide response. Patients 2 and 3 got a single islet graft. Patient 1 got a second graft

\*6 months after the first one. Patient 4 got a second graft

†7 days after the first one and

‡a third graft 6 months after the first.

### Imaging. {#s13}

Abdominal MRI was scheduled only if necessary, to exclude the occurrence of post-TX peritoneal lesions.

Site of transplant and intervention procedure {#s14}
---------------------------------------------

All patients received a transplant of microencapsulated HIs intraperitoneally, under ecography guidance and local anesthesia. The encapsulated islet suspension in saline was placed in a 60-mL syringe barrel and slowly delivered through a polypropylene catheter into the peritoneal cavity through a small incision of the abdominal wall. The injected total graft volume did not exceed 100 mL (capsules + saline). Patient 4, on his third TX, underwent abdominal laparoscopy, under general anesthesia, to visually select and optimize the TX site and possibly avoid capsule injection errors (see patient 1). In this instance, the microcapsules were evenly distributed beneath the liver and the spleen, where blood supply is high. In all TX procedures, care was taken to dispense the capsular suspension as thoroughly as possible, to prevent formation of capsules clusters. Human islet dosing varied between recipients, ranging from 5,000 to 15,000 IEQ/kg/TX (range 540,000--1,600,000 IEQ/patient). This result strictly depended on organ availability and the islet isolation rate per pancreas.

RESULTS {#s15}
=======

Clinical outcome {#s16}
----------------

None of the TX recipients showed any acute, significant postoperatory side effects. BG levels were stable, both short and long term after TX. In particular, throughout 24 months of TX, daily mean BG was stable in all patients, whereas after such time, the values tended to slightly but progressively raise. Interestingly, patient 1, who had suffered for severe nocturnal hypoglycemic episodes, showed evident recovery, in conjunction with stabilization of BG profiles. The natural history of this pilot study is summarized in [Table 1](#T1){ref-type="table"}, throughout 3 consecutive years of post-TX follow-up. At this time, the study was terminated and the patients were seen once a year. So far, at 7 years post-TX, all patients are in good health and are fully back to their original exogenous insulin therapy regimens.

Immunological findings {#s17}
----------------------

As a unique finding, no anti-MHC class I--II or anti-GAD65 antibodies or islet cell antibodies were detected in any of the transplanted patients throughout 5 years of post-TX follow-up ([Table 1](#T1){ref-type="table"}).

Microcapsule retrieval {#s18}
----------------------

Patient 1, 5 years after TX, back to his original insulin schedule, started complaining of abdominal discomfort. In our Center, upon palpation of the abdomen, we found a small mass that ultrasound scan identified as a hyperechoic cyst-like formation. The cyst, situated in the rectus anterior muscle, was surgically removed and consisted of a 3- to 4-cm fibrotic lump that contained mostly intact capsules with no more viable islet cells inside. Obviously, the original capsules, in this instance, had been mistakenly injected beneath the muscle fascia rather than intraperitoneally, thus resulting in the cyst formation.

CONCLUSIONS {#s19}
===========

Our alginate/polyaminoacidic encapsulation system has been confirmed to represent a powerful tool for immunoprotection of HI grafts ([@B5]), as proven by the absence of a wide array of islet cell-directed as well as anti-MHC class I--II antibodies ([@B6]). Hence, microcapsules provided the islet grafts with bioinvisibility, according to U.S. Food and Drug Administration criteria. In our opinion, this was the most important finding of the study. Obviously, the partial and transient metabolic benefits obtained by the treatment reflect limitations of this microcapsules generation, with special regard to their size in relation to TX site. Moreover, HIs can be moved through long distances with no loss of their viability and function ([@B7]). We maintain that smaller-size microcapsules could permit access to TX sites possibly associated with better functional exchange, thereby complying, more efficiently, with metabolic requirements of patients with T1DM.

Clinical trial reg. no. ISRCTN43557935, [www.isrctn.org](http://www.isrctn.org).
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